Annual report pursuant to Section 13 and 15(d)

SEGMENT INFORMATION

v3.22.4
SEGMENT INFORMATION
 12 Months Ended
Oct. 31, 2022
Segment Reporting [Abstract]  
SEGMENT INFORMATION

9. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280, Segment Reporting (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the years ended October 31, 2022 and 2021:

 

    2022     2021  
    Year Ended October 31,  
    2022     2021  
Net income (loss):                
CAR-T Therapeutics   $ (5,776 )   $ (5,673 )
Cancer Vaccines     (4,889 )     (4,559 )
Anti-Viral Therapeutics     (3,075 )     (2,928 )
Other     (31 )     32  
Total   $ (13,771 )   $ (13,128 )
                 
Total operating costs and expenses   $ 13,875     $ 13,648  
Less non-cash share-based compensation     (6,655 )     (8,058 )
Operating costs and expenses excluding non-cash share-based compensation   $ 7,220     $ 5,590  
                 
Operating costs and expenses excluding non-cash share based compensation:                
CAR-T Therapeutics   $ 3,206     $ 2,422  
Cancer Vaccines     2,355       1,642  
Anti-Viral Therapeutics     1,634       1,080  
Other     25       446  
Total   $ 7,220     $ 5,590  

 

    2022     2021  
    October 31,  
    2022     2021  
Total assets:                
CAR-T Therapeutics   $ 16,921     $ 15,068  
Cancer Vaccines     9,442       13,277  
Anti-Viral Therapeutics     3,811       7,368  
Other     238       544  
Total   $ 30,412     $ 36,257  

 

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

 

The Company’s consolidated revenue of $512,000 and inventor royalties, contingent legal fees, litigation and licensing expense of $385,000, for the year ended October 31, 2021 were solely related to our patent licensing segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located.